(Total Views: 639)
Posted On: 03/09/2021 10:26:51 PM
Post# of 154142
Re: longtimelong #82446
Here’s a recommendation to investors:
Ask NP next CC (should be soon) if CYDY has banked samples from the combo trial (which ended back in 2018). I believe the answer is no. That will make it difficult to conduct the RO on those patients and is likely contributing to the delay.
Incelldx ran RO tests for some of the monotherapy trial patients and they are in possession of the data, which Dr. Patterson has said looks great. Incelldx has a kit for CCR5 RO that has been used by BPs, not just CYDY, and is still available for CYDY to use.
The issue, in my option, is how to collect RO from combo and monotherapy patients who are no longer in the trial and who CYDY does not have banked samples for (likely all the combo and mono therapy patients).
Ask NP next CC (should be soon) if CYDY has banked samples from the combo trial (which ended back in 2018). I believe the answer is no. That will make it difficult to conduct the RO on those patients and is likely contributing to the delay.
Incelldx ran RO tests for some of the monotherapy trial patients and they are in possession of the data, which Dr. Patterson has said looks great. Incelldx has a kit for CCR5 RO that has been used by BPs, not just CYDY, and is still available for CYDY to use.
The issue, in my option, is how to collect RO from combo and monotherapy patients who are no longer in the trial and who CYDY does not have banked samples for (likely all the combo and mono therapy patients).
(4)
(0)
